Cytotoxic Benzodiazepine Derivatives
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/443,062, filed Feb 15, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,889,669 | Cytotoxic Benzodiazepine Derivatives In force · High confidence UsedRemaining | ImmunoGen, Inc. | In force | High confidence | ||
| US 9,169,272 | Cytotoxic Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | ||
| US 9,840,564 | Cytotoxic Benzodiazepine Derivatives In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | ||
| US 10,179,818 | Cytotoxic Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | ||
| US RE49,918 | Cytotoxic Benzodiazepine Derivatives In force · Low confidence | ImmunoGen, Inc. | In force | Low confidence | ||
| US 8,765,740 | Cytotoxic Benzodiazepine Derivatives In force · High confidence | ImmunoGen, Inc. | In force | High confidence | ||
| US 10,570,212 | Cytotoxic Benzodiazepine Derivatives Surrendered on reissue Apr 16, 2024 High confidence | ImmunoGen, Inc. | Surrendered on reissue Apr 16, 2024 | High confidence | ||
| US 9,434,748 | Cytotoxic Benzodiazepine Derivatives Lapsed Sep 6, 2024 on the fee record High confidence | ImmunoGen, Inc. | Lapsed Sep 6, 2024 on the fee record | High confidence |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by ImmunoGen, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.